↓ Skip to main content

PLOS

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity

Overview of attention for article published in PLOS ONE, March 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
47 Mendeley
Title
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Published in
PLOS ONE, March 2012
DOI 10.1371/journal.pone.0033797
Pubmed ID
Authors

Ulf Schulze-Topphoff, Aparna Shetty, Michel Varrin-Doyer, Nicolas Molnarfi, Sharon A. Sagan, Raymond A. Sobel, Patricia A. Nelson, Scott S. Zamvil

Abstract

Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how laquinimod promotes immune modulation. Oral laquinimod treatment reversed established RR-EAE and was associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells (Treg). In vivo laquinimod treatment inhibited donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included a decrease in CD11c(+)CD11b(+)CD4(+) dendritic cells (DC) and an elevation of CD11b(hi)Gr1(hi) monocytes. CD11b(+) cells from these mice exhibited an anti-inflammatory type II phenotype characterized by reduced STAT1 phosphorylation, decreased production of IL-6, IL-12/23 and TNF, and increased IL-10. In adoptive transfer, donor type II monocytes from laquinimod-treated mice suppressed clinical and histologic disease in recipients with established EAE. As effects were observed in both APC and T cell compartments, we examined whether T cell immune modulation occurred as a direct effect of laquinimod on T cells, or as a consequence of altered APC function. Inhibition of Th1 and Th17 differentiation was observed only when type II monocytes or DC from laquinimod-treated mice were used as APC, regardless of whether myelin-specific T cells were obtained from laquinimod-treated or untreated mice. Thus, laquinimod modulates adaptive T cell immune responses via its effects on cells of the innate immune system, and may not influence T cells directly.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 4%
United States 1 2%
Unknown 44 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 38%
Professor > Associate Professor 6 13%
Student > Bachelor 5 11%
Student > Ph. D. Student 5 11%
Other 3 6%
Other 6 13%
Unknown 4 9%
Readers by discipline Count As %
Agricultural and Biological Sciences 12 26%
Medicine and Dentistry 8 17%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Neuroscience 5 11%
Immunology and Microbiology 4 9%
Other 5 11%
Unknown 8 17%